相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues
C. Gridelli et al.
LUNG CANCER (2011)
NF-κ-Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by Von Hippel-Lindau Inactivation in Renal Cell Carcinomas
Allan J. Pantuck et al.
CANCER RESEARCH (2010)
Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer
Corinne Dahinden et al.
CLINICAL CANCER RESEARCH (2010)
Identification of Ror2 as a Hypoxia-inducible Factor Target in von Hippel-Lindau-associated Renal Cell Carcinoma
Tricia M. Wright et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Gillian L. Dalgliesh et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
Patricia Mambou Gwanmesia et al.
BMC CANCER (2009)
Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals
Xiang H. -F. Zhang et al.
CANCER CELL (2009)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2009)
Renal Cystic Diseases and Renal Neoplasms: A Mini-Review
Stephen M. Bonsib
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer
Rebecca E. Schweppe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Resistance to targeted therapy in renal-cell carcinoma
Brian I. Rini et al.
LANCET ONCOLOGY (2009)
MoKCa database - mutations of kinases in cancer
Christopher J. Richardson et al.
NUCLEIC ACIDS RESEARCH (2009)
Kidney Cancer: Now Available in a New Flavor
William G. Kaelin
CANCER CELL (2008)
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy
Sandra Turcotte et al.
CANCER CELL (2008)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
Kiran Gupta et al.
CANCER TREATMENT REVIEWS (2008)
The Csk-binding protein PAG regulates PDGF-induced src mitogenic signaling via GM1
Laurence Veracini et al.
JOURNAL OF CELL BIOLOGY (2008)
Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
Ralf Buettner et al.
MOLECULAR CANCER RESEARCH (2008)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Paul H. Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Treatment outcome for metastatic papillary renal cell carcinoma patients
Ellen A. Rormen et al.
CANCER (2006)
Stromal Derived Factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis
Judong Pan et al.
MOLECULAR CANCER (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling
IK Lund et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2005)
The role of protein tyrosine phosphatase 1B in Ras signaling
N Dube et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src
PA Plé et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
c-Src and cooperating partners in human cancer
R Ishizawar et al.
CANCER CELL (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Role of VHL gene mutation in human cancer
WY Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
NK Janzen et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α
DA Chan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
K Kondo et al.
CANCER CELL (2002)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
